FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
Can rivaroxaban improve cardiovascular outcomes in patients with advanced CKD.? Although vascular inflammation and thrombosis are at the heart of CV damage, anticoagulants have not previously shown benefits in CVD patients.
This week, NephJC will discuss whether obinutuzumab is ready to outperform tacrolimus in primary membranous nephropathy
In this edition of NephJC, we discuss the largest case series of kidney biopsies in patients with Diabetes.
FIND-CKD extends finerenone beyond diabetic kidney disease, showing slower eGFR decline and sustained albuminuria reduction in non-diabetic CKD. While the benefits are modest and cardiovascular effects remain uncertain, the trial opens the door to broader use of nsMRAs and raises important questions about combination therapy with SGLT2 inhibitors.
Is finerenone ready to move beyond diabetes?
The FIND-CKD phase 3 arrived from the #ERA26 and is the first one to show kidney protection with finerenone in non-diabetic CKD.
The next challenge is no longer whether finerenone belongs in non-diabetic CKD, but how to best combine with the rest of the pillars to maximize protection.
Check out the newest VA created by our intern Raquel Barba
¿Está la finerenona lista para ir más allá de la diabetes?
El estudio FIND-CKD recien llegado del #ERA26, es el primer ensayo fase 3 que demuestra protección renal con finerenona en pacientes con ERC no diabética.
El siguiente reto ya no es si la finerenona tiene un lugar en la ERC no diabética, sino cómo combinarla de la mejor manera con el resto de los pilares del tratamiento para maximizar la protección renal.
No se pierdan el nuevo Visual Abstract creado por nuestra interna Raquel Barba
Fresh from the #ERA26 Late-Breaking Clinical Trials, the MAJESTY study compared obinutuzumab with tacrolimus and raises important questions about the future of anti-CD20 therapy.
👑 Is deeper B-cell depletion enough to claim the throne?
📖 Check out the latest Visual Abstract by Dr Divya Bajpai
Recién llegado desde #ERA26, el estudio MAJESTY comparó obinutuzumab frente a tacrolimus y plantea importantes interrogantes sobre el futuro de las terapias anti-CD20 en la nefropatía membranosa primaria.
👑 ¿Será suficiente una depleción más profunda de células B para reclamar el trono?
📖 Revisa el más reciente resumen visual elaborado por la Dra Divya Bajpai
This week we will discuss whether a bundled, team-based hypertension intervention- featuring intensive BP targets, home monitoring, health coaching, and audit feedback- can overcome poverty, clinical inertia, and fragmented care to improve blood pressure control in low-income patients receiving care at federally qualified health centers.
Can multifaceted strategies improve hypertension control in low-income patients?
Hypertension remains one of the leading cardiovascular risk factors worldwide. However, achieving adequate blood pressure control continues to be a major challenge, especially in low-income populations. The IMPACTS-BP trial has arrived, a study evaluating whether a multifaceted team-based strategy can improve blood pressure control and adherence to antihypertensive therapy.
Check out the VA by Dra Akshaya Jayachandran, and don’t forget to join the live discussion with @NephJC on X and Bluesky
¿Puede el trabajo colaborativo mejorar el control de la hipertensión?
La hipertensión arterial continúa siendo uno de los principales factores de riesgo cardiovascular a nivel mundial. Sin embargo, lograr un adecuado control de la presión arterial sigue siendo un desafío, especialmente en poblaciones de bajos ingresos. Hoy aterriza el ensayo IMPACTS-BP, un estudio que evaluó si una estrategia multifacética basada en equipos puede mejorar el control y la adherencia al tratamiento antihipertensivo.
Revisa el resumen visual realizado por la Dra Akshaya Jayachandran y no olvides unirte en vivo con @NephJC en X y Bluesky
¿Elevar el K⁺ al rango alto-normal puede reducir las descargas del DAI y las hospitalizaciones? POTCAST desafía nuestro miedo al potasio.
Revisa el resumen visual por Jeyakumar Meyyappan y únete a la conversación en #NephJC
Can pushing K⁺ to the high-normal range reduce ICD shocks and hospitalizations? POTCAST challenges our fear of potassium.
Check out the VA by Jeyakumar Meyyappan and join the #NephJC conversation
Check out VALIANT recap: a 26-week analysis of the phase 3 trial of pegcetacoplan in C3GN! Thread by NephJC intern Bogdan Agavriloaei.
1/10 Last #NephJC we discussed pegcetacoplan in C3 glomerulopathy and Immune-Complex MPGN #TenPostNephJC
— Nephrology Journal Club (@NephJC) January 16, 2026
Given the central role of complement dysregulation in C3GN, the 🔑 question was whether 🎯 complement inhibition could deliver clinical benefithttps://t.co/1GyC3P8emi pic.twitter.com/Hllq7tEJaG
Check out PISCES recap: a whale of a tale of fish oil and cardio-protection in ESRD! Thread by NephJC intern Sai Vani
Check out ORIGIN 3 recap: a 36-week, interim analysis of phase 3 trial of atacicept in IgAN! Thread by NephJC intern Marc Soco.
1/10 Last #NephJC we discussed the ORIGIN 3 trial which investigated the use of Atacicept in IgAN #TenPostNephJC
— Nephrology Journal Club (@NephJC) November 24, 2025
Read the @NEJM article 👇 https://t.co/yBMbZtb7XG pic.twitter.com/6vp0tROznZ
Stunning visual abstract summarizing NEJM study, by Priti Meena
How low is too low for blood pressure? Will BPROAD get to the bottom of this issue?
